Gilead Sciences, Inc. (GILD) on Wednesday announced detailed 48-week results from a Phase 3 study, or Study 1878, that evaluates the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor or bPI to a fixed-dose combination of bictegravir (50 mg), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone.
from RTT - Biotech http://ift.tt/2wxMV5W
via IFTTT
No comments:
Post a Comment